PAN 811

Drug Profile

PAN 811

Alternative Names: PAN-811

Latest Information Update: 29 Jun 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Antidementias; Cytoprotectives; Neuroprotectants; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Antioxidants; Chelating agents; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Stroke

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,
  • 21 Jul 2006 Data presented at the 10th International conference on Alzeimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's disease pharmacodynamics section
  • 09 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Alzheimer's Disease and cognition disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top